Carlos Vera, MD
Family Medicine · Westminster, CONPI 1023109188
Payments from drug & device makers
Across 359 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$852
- AstraZeneca$777
- Boehringer Ingelheim$683
- AbbVie$501
- Bayer$276
- plus $2K from 28 others
What the payments were for
- Travel & lodging$60%
- Food & beverage$6,28599%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 72 | $1,174 |
| Lilly USA, LLC | 53 | $852 |
| AstraZeneca | 41 | $777 |
| Boehringer Ingelheim | 35 | $683 |
| AbbVie(2 entities) | 27 | $501 |
| Bayer | 13 | $276 |
| Abbott | 12 | $248 |
| Pfizer | 13 | $197 |
| GSK | 12 | $186 |
| Amarin Pharma, Inc. | 8 | $146 |
| Sanofi-aventis U.S. LLC | 9 | $139 |
| Genentech USA, Inc. | 7 | $129 |
| Exact Sciences | 5 | $123 |
| Nestle Healthcare Nutrition Inc. | 5 | $89 |
| Amgen | 4 | $88 |
| Eisai Inc. | 5 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $70 |
| Astellas Pharma US Inc | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 3 | $61 |
| Cranial Technologies, Inc | 3 | $54 |
| Alfasigma USA, Inc. | 3 | $53 |
| Sanofi Pasteur Inc. | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $37 |
| Gilead | 2 | $35 |
| Biogen | 2 | $33 |
| Merck | 2 | $29 |
| Medtronic(2 entities) | 2 | $27 |
| PBG Puerto Rico LLC | 1 | $25 |
| Novartis | 1 | $20 |
| Dermira, Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$109
How this compares
$6,347 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 113 | $140,164 |
| OzempicSemaglutide | 65 | $72,812 |
| EliquisApixaban | 58 | $71,803 |
| FarxigaDapagliflozin Propanediol | 35 | $32,078 |
| TrulicityDulaglutide | 26 | $26,451 |
| VascepaIcosapent Ethyl | 17 | $16,891 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $13,832 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $10,382 |
| Spiriva RespimatTiotropium Bromide | 19 | $10,009 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $9,200 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $8,388 |
| OxycontinOxycodone Hcl | 13 | $7,991 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $7,194 |
| Fentanyl | 11 | $5,037 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $4,761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $683 | $160,555143 claims |
| Novo NordiskOzempic | $1,174 | $72,81265 claims |
| PfizerEliquis | $197 | $71,80358 claims |
| AstraZenecaFarxiga, Symbicort | $777 | $40,46658 claims |
| Lilly USA, LLCTrulicity | $852 | $26,45126 claims |
| GSKAnoro Ellipta, Incruse Ellipta | $186 | $11,22122 claims |
| AbbVieSynthroid | $501 | $1,73830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Westminster
- Erik KramerWestminster$104K
- Gregory MaederWestminster$95K
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
- Timothy ColanderAurora$3.1M
- Mia ScottDenver$993K
- Matthew LewisAurora$960K
- Ethan LazarusDenver$688K
- Patrick BarryFraser$568K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.